9 intracellular single-chain antibodies for gene therapy

Related Experiment Video

Updated: Jun 3, 2026

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
12:28

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Published on: October 15, 2016

G Bilbao1, J Gomez-Navarro, K Kazano

  • 1Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL.

Methods in Molecular Medicine
|March 11, 2011
PubMed

Insights

Researchers are exploring three novel cancer therapies targeting the molecular basis of cancer: mutation compensation, molecular chemotherapy, and genetic immunotherapy. These strategies aim for targeted intervention, with early-phase clinical trials underway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Understanding the molecular basis of cancer enables targeted therapeutic interventions.
  • Traditional cancer treatments often lack specificity, leading to side effects.
  • The need for more precise and effective cancer therapies is critical.

Purpose of the Study:

  • To outline three primary molecular-level strategies for cancer intervention: mutation compensation, molecular chemotherapy, and genetic immunotherapy.
  • To describe the mechanisms and goals of each therapeutic approach.
  • To report the initiation of Phase I clinical trials for these novel strategies.

Main Methods:

  • Mutation compensation: correcting genetic defects via oncogene ablation, tumor suppressor gene replacement, or signal transduction pathway interference.
  • Molecular chemotherapy: enhancing drug delivery specificity or patient tolerance to chemotherapy.
  • Genetic immunotherapy: boosting the immune system's response to tumors.

Main Results:

  • All three conceptual approaches have progressed to Phase I human clinical trials.
  • These trials are designed to evaluate dose escalation, safety, and toxicity.
  • Early data from these trials will inform future therapeutic development.

Conclusions:

  • Novel molecular-based cancer therapies show promise for targeted intervention.
  • Mutation compensation, molecular chemotherapy, and genetic immunotherapy represent distinct yet complementary strategies.
  • Advancement to clinical trials signifies a critical step in validating these innovative cancer treatments.

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...